Sanofi(US:SNY) Ge Long Hui A P P·2025-10-24 09:20Core Insights - Sanofi (SNY.US) shares rose 2.7% in pre-market trading following the announcement of third-quarter profits that exceeded analyst expectations, driven primarily by strong demand for its best-selling drugs Dupixent in the dermatology and asthma sectors [1] Financial Performance - Sanofi reported third-quarter revenue of €12.43 billion, representing a year-over-year increase of 2.3% [1] - The earnings per share (EPS) for the quarter was €2.91, surpassing the average analyst estimate of €2.65 [1] Future Outlook - For the full year 2025, Sanofi maintains its forecast of high single-digit percentage sales growth at constant exchange rates [1] - The company also anticipates a "strong" rebound in earnings per share, with growth expected to reach low double-digit percentages [1]